Literature DB >> 6692364

Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.

M J Brunda, D Rosenbaum.   

Abstract

The ability of two subtypes of recombinant human alpha interferons (IFN), rIFN-alpha A and rIFN-alpha D, and two intramolecular hybrids, rIFN-alpha A/D and rIFN-alpha D/A, to modulate murine natural killer (NK) cell activity in vitro and in vivo was examined. The cytotoxic activity of murine spleen cells was markedly augmented by rIFN-alpha A/D following in vitro incubation, while the other IFN had little or no effect. The augmentation observed was dose dependent and inhibited by monoclonal antibody to rIFN-alpha A/D. Mice treated by one of several routes with rIFN-alpha A/D had elevated levels of NK activity in their spleen, peritoneal cavity, and peripheral blood following one to three daily injections. Augmentation of cytotoxicity was dose dependent in vivo and was less efficient or absent following treatment with the other recombinant IFN. When treatment was extended to ten or 12 daily i.p. injections, marked differences in NK levels resulted, depending upon the location from which cells were obtained. Following prolonged administration of rIFN-alpha A/D, a significant decrease in NK activity was seen with peripheral blood lymphocytes, while peritoneal cells retained elevated levels of activity; in spleen, NK activity was less than in mice treated for 3 days with rIFN-alpha A/D but greater than in control mice. Treatment of mice in vivo with IFN can either increase or decrease NK levels dependent upon both the length of treatment and the site at which the NK activity is measured. The use of rIFN-alpha A/D with murine cells is an excellent model to study the regulation of NK activity by IFN.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692364

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice.

Authors:  P N Gilles; G Fey; F V Chisari
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.

Authors:  B Sredni; Y Kalechman; M Albeck; O Gross; D Aurbach; P Sharon; S N Sehgal; M J Gurwith; H Michlin
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

3.  Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes.

Authors:  S W Mamus; S Beck-Schroeder; E D Zanjani
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

4.  Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.

Authors:  J E Talmadge; M A Chirigos
Journal:  Springer Semin Immunopathol       Date:  1985

5.  Use of recombinant bovine alpha 1 interferon in reducing respiratory disease induced by bovine herpesvirus type 1.

Authors:  L A Babiuk; M J Lawman; G A Gifford
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

6.  Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

Authors:  C Milanese; A Salmaggi; L La Mantia; A Campi; M Eoli; M Savoiardo; G Bianchi; A Nespolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

7.  CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; Rhona Stein; Chien-Hsing Chang
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

8.  The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.

Authors:  Béatrice Clémenceau; Régine Vivien; Catherine Pellat; Michael Foss; Gilles Thibault; Henri Vié
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

9.  Antitumor and antimetastatic activities of human recombinant interferon alpha A/D.

Authors:  J Nishimura; K Mitsui; T Ishikawa; Y Tanaka; R Yamamoto; Y Suhara; H Ishitsuka
Journal:  Clin Exp Metastasis       Date:  1985 Oct-Dec       Impact factor: 5.150

10.  Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.

Authors:  Y Fujimiya; W C Chang; A Bakke; D Horwitz; P K Pattengale
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.